Back to Search Start Over

Power Considerations in Designing and Interpreting Adaptive Clinical Trials.

Authors :
Wang R
Mehta C
Source :
NEJM evidence [NEJM Evid] 2024 Jan; Vol. 3 (1), pp. EVIDe2300309. Date of Electronic Publication: 2023 Dec 26.
Publication Year :
2024

Abstract

Adaptive clinical trials allow researchers to make preplanned modifications based on accumulating data from an ongoing trial while preserving the trial's integrity and validity. These modifications may include early termination in cases of successes or lack of efficacy, refining the sample size, altering treatments or doses, or focusing recruitment efforts on individuals most likely to benefit. In this issue of NEJM Evidence , Geisler et al. <superscript>1</superscript> report results from the Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS) trial, a multicenter randomized trial of apixaban compared with aspirin in patients with cardioembolism risk factors.

Details

Language :
English
ISSN :
2766-5526
Volume :
3
Issue :
1
Database :
MEDLINE
Journal :
NEJM evidence
Publication Type :
Editorial & Opinion
Accession number :
38320521
Full Text :
https://doi.org/10.1056/EVIDe2300309